BIO-Europe Spring: Pharma Dealmaking in Lisbon
CNS may finally be emerging from its long discussed graveyard. Oncology dealmaking is becoming more selective. And sourcing innovation from China is no longer something to be coy about. These were some of my takeaways from BIO-Europe Spring in Lisbon last week, where the Evaluate team was on the ground sharing data led insight on […]
Three Things we Learned in our 2026 Orphan Drugs Webinar
Orphan drugs are forecast to make up 21% of all prescription drug sales by 2032, according to Evaluate forecasts. So it’s hardly surprising that we had a lot of interest in our latest orphan drugs market webinar. If you missed it, you can find the on-demand version here. If you’re saving that treat for later, […]
Orphan Drugs at a Crossroads: Bigger Numbers, Tougher Calls
Drugs for rare diseases have played an increasingly significant role in the biopharma market for years. I’ve been working on Evaluate’s annual orphan drugs report for the past five years and it’s clear from looking at the evolution of the data in that time that orphans offer considerable opportunity. We’ve just published this year’s report, […]
Three Things we Learned in our 2026 Preview Webinar
Obesity. China. FDA turmoil. Our pharma 2026 Preview webinar was not the place to look for a change in the big pharma buzzwords for this year. These big themes remain with us for now. But there was still plenty for our expert panel to discuss during the session. If you missed it, you can catch […]
Three Things we Learned in our Unlocking Innovation in Pharma Webinar
There is life beyond ADCs and GLP-1s. Given the level of attention these particular areas have received in recent years, it can be hard to remember that – but it was a key message from our recent webinar, “Unlocking Innovation: What pharma deals reveal about tomorrow’s therapies”. Our business development and licensing experts investigated where […]
Three Things We Learned in our Corporate-Level Competitive Intelligence Webinar
Our Competitive Intelligence consulting team has been busy recently. Fresh from presenting at Pharma CI, Kelly Chamberlain led our latest webinar, “Mind the Gap: Supporting Cross-Functional Teams with Corporate Level CI”. She was joined by Paul D’Souza and Amanda Micklus and Paul is straight off to Pharma Cimicon in Berlin to share his wisdom with […]
How Can Analogs Help Pharma Companies Forecast Effectively?
When you’re bringing a new drug to market, one of the many forecasting challenges is the ability to root your forecasts in reality. This is where analogs come in. Analogs are a really powerful forecasting tool and by selecting a suite of analogs can enable forecasters to take the past and use it as a […]
What’s the role of Excel in a Forecaster’s Software Toolkit?
There are many challenges that biopharma forecasters face but perhaps one of the greatest is asking people to change their behavior. No matter how many fancy forecasting tools and solutions you may have, people know what they like and one thing they like is Excel. In this video, I talk about why there is still […]
Three Things we Learned in our World Preview 2025 Webinar
Every year, I am hugely fortunate to work with our team of experts to create the Evaluate World Preview report. Now in its 18th year, the World Preview offers a data-rich look at the future of the pharmaceutical industry. It’s full of forecast data that help to paint a picture of the shifting sands of […]
How can Pharma Navigate Turbulent Seas? Find out in our World Preview Webinar
The Evaluate World Preview report is a staple of the pharma calendar. The 2025 edition has just been published, marking the 18th year of providing forecast and trend insights to decision makers across the industry. If you’re not familiar with the World Preview, I recommend taking a look. Not only does it provide a wealth […]
